Your browser doesn't support javascript.
loading
Characterization of cannabis use by patients with myotonic dystrophy type 1: A pilot study.
Beauchesne, William; Savard, Catherine; Côté-Hamel, Marika; Poliquin, Émilie; Gagné-Ouellet, Valérie; Gagnon, Cynthia; Tremblay, Karine.
Afiliación
  • Beauchesne W; Pharmacology-physiology Department, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (Chicoutimi University Hospital), Saguenay, QC, Canada.
  • Savard C; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (Chicoutimi University Hospital), Saguenay, QC, Canada; Family Medicine and Emergency Department, Université de Sherbrooke, Saguenay, QC, Canada.
  • Côté-Hamel M; Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Jonquière, QC, Canada.
  • Poliquin É; Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Jonquière, QC, Canada.
  • Gagné-Ouellet V; Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Jonquière, QC, Canada.
  • Gagnon C; Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Jonquière, QC, Canada; Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-St-Jean sur les innovations en santé, Sherbrooke University, Longueuil/Saguenay, QC, Canada.
  • Tremblay K; Pharmacology-physiology Department, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean (Chicoutimi University Hospital), Saguenay, QC, Canada; Centre de Recherche Charles-Le-Moyne-Saguenay-Lac-St-Jean sur les innova
Neuromuscul Disord ; 31(3): 226-231, 2021 03.
Article en En | MEDLINE | ID: mdl-33509648
The treatment of myotonic dystrophy type 1 (DM1) focuses on reducing symptom burden. However, since medication often fails to produce satisfying symptom relief, some patients seek alternatives, such as cannabis, to help reduce some of these symptoms. The aim of this study was to provide an accurate profile of cannabis use among DM1 patients. Phone interviews were conducted to identify current and former users, and to assess reasons for cannabis use. Characteristics of cannabis use were also investigated. Briefly, among the 72 study participants, 22.2% currently used cannabis and a majority of them (56.9%) reported using it to relieve symptoms associated with DM1. These users, classified as therapeutic users, reported poorer health status (EQ-5D index scores: 0.532±0.230 vs. 0.823±0.208, p = 0.020; EQ-VAS scale 50.56±10.74 vs. 75.57±21.50, p = 0.009) than non-therapeutic users. Finally, differences among sex were also highlighted. While the therapeutic effects of cannabis were not explored in our study, our results support the potential role of cannabis and cannabinoids in the treatment of DM1-associated symptoms which will need to be thoroughly investigated.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uso de la Marihuana / Distrofia Miotónica Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Neuromuscul Disord Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uso de la Marihuana / Distrofia Miotónica Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Neuromuscul Disord Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido